1.湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院泌尿外科,长沙 410013
2.衡阳市南华大学附属第二医院泌尿外科,衡阳 421001
3.萍乡市人民医院泌尿外科,萍乡 337000
Received:17 May 2023,
Revised:2023-07-23,
Accepted:28 August 2023,
Published:28 August 2023
移动端阅览
裴夏明,李鸿,梁宇,等.生物标志物炎症因子、细胞焦亡因子和铁死亡因子在膀胱癌治疗与预后中的价值[J].重庆医科大学学报,2023,48(8):863-868.
Pei Xiaming,Li Hong,Liang Yu,et al.Value of inflammatory,pyroptosis,and ferroptosis biomarkers in the treatment and prognosis of bladder cancer[J].Journal of Chongqing Medical University,2023,48(8):863-868.
裴夏明,李鸿,梁宇,等.生物标志物炎症因子、细胞焦亡因子和铁死亡因子在膀胱癌治疗与预后中的价值[J].重庆医科大学学报,2023,48(8):863-868. DOI: 10.13406/j.cnki.cyxb.003316.
Pei Xiaming,Li Hong,Liang Yu,et al.Value of inflammatory,pyroptosis,and ferroptosis biomarkers in the treatment and prognosis of bladder cancer[J].Journal of Chongqing Medical University,2023,48(8):863-868. DOI: 10.13406/j.cnki.cyxb.003316.
根据2020年全球癌症统计,膀胱癌(bladder cancer,BC)是全球诊断率第十高的癌症,是男性第六常见的癌症和第九大癌症死因。尽管膀胱癌的确切原因尚不清楚,但已经确定了一些因素与膀胱癌风险增加相关,如吸烟、化学物质暴露、年龄、性别、遗传因素、环境因素等。BC会导致疼痛、尿路感染、尿失禁和死亡等,对患者的健康情况及经济造成巨大的影响。为了更好地预防和治疗BC,生物标志物的检测可以被用来监测或预测BC的存在、进展或治疗效果。近年来,研究表明,BC的发展与炎症、细胞焦亡、铁死亡等分子机制密切相关。越来越多的研究也关注到这些分子机制相关的生物标志物在BC中的应用。本综述将探讨这些新型生物标志物在BC诊断、治疗与预后中的价值,为进一步在膀胱癌治疗的不同阶段有针对性地靶向上述分子,以达到控制疾病、延长无病间期、抑制肿瘤复发和转移的目的。
According to Global Cancer Statistics 2020,bladder cancer is the tenth most commonly diagnosed cancer worldwide,which is the sixth most common cancer and the ninth leading cause of cancer-related death in men. Although the exact pathogenesis of bladder cancer is unclear,certain factors have been demonstrated to be associated with an increased risk of bladder cancer,such as smoking,chemical exposure,age,sex,genetic factors,and environmental factors. Bladder cancer can cause pain,urinary tract infection,urinary incontinence,and death,which can impose a huge health and economic burden on patients. To better prevent and treat bladder cancer,the detection of biomarkers can help monitor or predict the development,progression,or treatment of bladder cancer. In recent years,studies have shown that the development of bladder cancer is closely related to various mechanisms including inflammation,pyroptosis,and ferroptosis,and these molecular mechanisms-related biomarkers have been increasingly applied in the research of bladder cancer. This review focuses on the value of these novel biomarkers in the diagnosis,treatment,and prognosis of bladder cancer,which can be potential targets at different treatment stages of bladder cancer for controlling the disease,prolonging disease-free interval,and inhibiting tumor recurrence and metastasis.
Sung H , Ferlay J , Siegel RL , et al . Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 .
Antoni S , Ferlay J , Soerjomataram I , et al . Bladder cancer incidence and mortality:a global overview and recent trends [J ] . Eur Urol , 2017 , 71 ( 1 ): 96 - 108 .
Cumberbatch MGK , Jubber I , Black PC , et al . Epidemiology of bladder cancer:a systematic review and contemporary update of risk factors in 2018 [J ] . Eur Urol , 2018 , 74 ( 6 ): 784 - 795 .
Ferlay J , Randi G , Bosetti C , et al . Declining mortality from bladder cancer in Europe [J ] . BJU Int , 2008 , 101 ( 1 ): 11 - 19 .
Abdollah F , Gandaglia G , Thuret R , et al . Incidence,survival and mortality rates of stage-specific bladder cancer in United States:a trend analysis [J ] . Cancer Epidemiol , 2013 , 37 ( 3 ): 219 - 225 .
Mossanen M . The epidemiology of bladder cancer [J ] . Oncol Clin N Am , 2021 , 35 ( 3 ): 445 - 455 .
Liu X , Jiang J , Yu C , et al . Secular trends in incidence and mortality of bladder cancer in China,1990-2017:a joinpoint and age-period-cohort analysis [J ] . Cancer Epidemiol , 2019 , 61 : 95 - 103 .
van Kessel KEM , van der Keur KA , Dyrskjøt L , et al . Molecular markers increase precision of the European association of urology non-muscle-invasive bladder cancer progression risk groups [J ] . Clin Cancer Res , 2018 , 24 ( 7 ): 1586 - 1593 .
Konieczkowski DJ , Efstathiou JA , Mouw KW . Contemporary and emerging approaches to bladder-preserving trimodality therapy for muscle-invasive bladder cancer [J ] . Hematol Oncol Clin North Am , 2021 , 35 ( 3 ): 567 - 584 .
Song D , Powles T , Shi L , et al . Bladder cancer,a unique model to understand cancer immunity and develop immunotherapy approaches [J ] . J Pathol , 2019 , 249 ( 2 ): 151 - 165 .
Casadei C , Dizman N , Schepisi G , et al . Targeted therapies for advanced bladder cancer:new strategies with FGFR inhibitors [J ] . Ther Adv Med Oncol , 2019 , 11 : 1758835919890285 .
Chang SS , Bochner BH , Chou R , et al . Treatment of nonmetastatic muscle-invasive bladder cancer:American urological association/american society of clinical oncology/american society for radiation oncology/society of urologic oncology clinical practice guideline summary [J ] . J Oncol Pract , 2017 , 13 ( 9 ): 621 - 625 .
Cumberbatch MG , Rota M , Catto JWF , et al . The role of tobacco smoke in bladder and kidney carcinogenesis:a comparison of exposures and meta-analysis of incidence and mortality risks [J ] . Eur Urol , 2016 , 70 ( 3 ): 458 - 466 .
Stern MC , Lin J , Figueroa JD , et al . Polymorphisms in DNA repair genes,smoking,and bladder cancer risk:findings from the international consortium of bladder cancer [J ] . Cancer Res , 2009 , 69 ( 17 ): 6857 - 6864 .
Cumberbatch MGK , Cox A , Teare D , et al . Contemporary occupational carcinogen exposure and bladder cancer:a systematic review and meta-analysis [J ] . JAMA Oncol , 2015 , 1 ( 9 ): 1282 - 1290 .
Janković S , Radosavljević V . Risk factors for bladder cancer [J ] . Tumori , 2007 , 93 ( 1 ): 4 - 12 .
Letašiová S , Medve'ová A , Šovčíková A , et al . Bladder cancer,a review of the environmental risk factors [J ] . Environ Health , 2012 , 11 ( Suppl 1 ): S11 .
Kamat AM , Hahn NM , Efstathiou JA , et al . Bladder cancer [J ] . Lancet , 2016 , 388 ( 10061 ): 2796 - 2810 .
Wang Z , Que H , Suo C , et al . Evaluation of the NMP22 BladderChek test for detecting bladder cancer:a systematic review and meta-analysis [J ] . Oncotarget , 2017 , 8 ( 59 ): 100648 - 100656 .
Washino S , Hirai M , Matsuzaki A , et al . Clinical usefulness of CEA,CA19-9,and CYFRA 21-1 as tumor markers for urothelial bladder carcinoma [J ] . Urol Int , 2011 , 87 ( 4 ): 420 - 428 .
Thomas L , Leyh H , Marberger M , et al . Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer [J ] . Clin Chem , 1999 , 45 ( 4 ): 472 - 477 .
Lokeshwar VB , Obek C , Soloway MS , et al . Tumor-associated hyaluronic acid:a new sensitive and specific urine marker for bladder cancer [J ] . Cancer Res , 1997 , 57 ( 4 ): 773 - 777 .
Wahren B , Nilsson B , Zimmerman R . Urinary CEA for prediction of survival time and recurrence in bladder cancer [J ] . Cancer , 1982 , 50 ( 1 ): 139 - 145 .
Lu Z , Tang F , Li Z , et al . Prognosis risk model based on pyroptosis-related lncRNAs for bladder cancer [J ] . Dis Markers , 2022 , 2022 : 7931393 .
Kong N , Chen X , Feng J , et al . Baicalin induces ferroptosis in bladder cancer cells by downregulating FTH1 [J ] . Acta Pharm Sin B , 2021 , 11 ( 12 ): 4045 - 4054 .
Gakis G . The role of inflammation in bladder cancer [J ] . Adv Exp Med Biol , 2014 , 816 : 183 - 196 .
陈怡 , 陈沛林 , 吕晓磊 , 等 . 膀胱癌尿路感染患者免疫和炎症因子的表达及临床诊断价值 [J ] . 中华医院感染学杂志 , 2022 , 32 ( 1 ): 80 - 84 .
Chen Y , Chen PL , Lü XL , et al . Expression of immune and inflammatory factors in bladder cancer patients with urinary tract infection and clinical diagnostic values [J ] . Chin J Nosocomiol , 2022 , 32 ( 1 ): 80 - 84 .
Shadpour P , Zamani M , Aghaalikhani N , et al . Inflammatory cytokines in bladder cancer [J ] . J Cell Physiol , 2019 , 234 ( 9 ): 14489 - 14499 .
Green J , Fuge O , Allchorne P , et al . Immunotherapy for bladder cancer [J ] . Res Rep Urol , 2015 : 65 .
Yang G , Shen W , Zhang Y , et al . Accumulation of myeloid-derived suppressor cells(MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer [J ] . Oncotarget , 2017 , 8 ( 24 ): 38378 - 38388 .
Chen MF , Lin PY , Wu CF , et al . IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer [J ] . PLoS One , 2013 , 8 ( 4 ): e61901 .
Liu J , Wang L , Wang T , et al . Expression of IL-23R and IL-17 and the pathology and prognosis of urinary bladder carcinoma [J ] . Oncol Lett , 2018 , 16 ( 4 ): 4325 - 4330 .
Reis ST , Leite KRM , Piovesan LF , et al . Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of bladder cancer [J ] . BMC Urol , 2012 , 12 : 18 .
Nonomura N , Tokizane T , Nakayama M , et al . Possible correlation between polymorphism in the tumor necrosis factor-beta gene and the clinicopathological features of bladder cancer in Japanese patients [J ] . Int J Urol , 2006 , 13 ( 7 ): 971 - 976 .
Marsh HP , Haldar NA , Bunce M , et al . Polymorphisms in tumour necrosis factor(TNF) are associated with risk of bladder cancer and grade of tumour at presentation [J ] . Br J Cancer , 2003 , 89 ( 6 ): 1096 - 1101 .
Kopparapu PK , Boorjian SA , Robinson BD , et al . Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer [J ] . Anticancer Res , 2013 , 33 ( 6 ): 2381 - 2390 .
Nazari A , Khorramdelazad H , Hassanshahi G . Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer [J ] . Int J Clin Oncol , 2017 , 22 ( 6 ): 991 - 1000 .
Huang CP , Liu LX , Shyr CR . Tumor-associated macrophages facilitate bladder cancer progression by increasing cell growth,migration,invasion and cytokine expression [J ] . Anticancer Res , 2020 , 40 ( 5 ): 2715 - 2724 .
Lu H , Wu J , Liang L , et al . Identifying a novel defined pyroptosis-associated long noncoding RNA signature contributes to predicting prognosis and tumor microenvironment of bladder cancer [J ] . Front Immunol , 2022 , 13 : 803355 .
Broz P , Pelegrín P , Shao F . The gasdermins,a protein family executing cell death and inflammation [J ] . Nat Rev Immunol , 2020 , 20 ( 3 ): 143 - 157 .
Wang Q , Wang Y , Ding J , et al . A bioorthogonal system reveals antitumour immune function of pyroptosis [J ] . Nature , 2020 , 579 ( 7799 ): 421 - 426 .
Du T , Gao J , Li P , et al . Pyroptosis,metabolism,and tumor immune microenvironment [J ] . Clin Transl Med , 2021 , 11 ( 8 ): e492 .
Anderson NM , Simon MC . The tumor microenvironment [J ] . Curr Biol , 2020 , 30 ( 16 ): R921 - R925 .
Zhao J , Wu C , Wang Y , et al . Identification of a pyroptosis related gene signature for predicting prognosis and estimating tumor immune microenvironment in bladder cancer [J ] . Transl Cancer Res , 2022 , 11 ( 7 ): 1865 - 1879 .
Yang GL , Zhang LH , Bo JJ , et al . Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer [J ] . J Surg Oncol , 2012 , 106 ( 1 ): 57 - 61 .
Wu T , Zhang W , Yang G , et al . HMGB1 overexpression as a prognostic factor for survival in cancer:a meta-analysis and systematic review [J ] . Oncotarget , 2016 , 7 ( 31 ): 50417 - 50427 .
Wu Z , Liu Q , Zhu K , et al . Cigarette smoke induces the pyroptosis of urothelial cells through ROS/NLRP3/caspase-1 signaling pathway [J ] . Neurourol Urodyn , 2020 , 39 ( 2 ): 613 - 624 .
Li P , Jiang M , Li K , et al . Glutathione peroxidase 4-regulated neutrophil ferroptosis induces systemic autoimmunity [J ] . Nat Immunol , 2021 , 22 ( 9 ): 1107 - 1117 .
Stockwell BR , Angeli JPF , Bayir H , et al . Ferroptosis:a regulated cell death nexus linking metabolism,redox biology,and disease [J ] . Cell , 2017 , 171 ( 2 ): 273 - 285 .
Yang L , Li C , Qin Y , et al . A novel prognostic model based on ferroptosis-related gene signature for bladder cancer [J ] . Front Oncol , 2021 , 11 : 686044 .
Xie Y , Zhu S , Song X , et al . The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity [J ] . Cell Rep , 2017 , 20 ( 7 ): 1692 - 1704 .
Yuan H , Li X , Zhang X , et al . CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation [J ] . Biochem Biophys Res Commun , 2016 , 478 ( 2 ): 838 - 844 .
Ingold I , Berndt C , Schmitt S , et al . Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis [J ] . Cell , 2018 , 172 ( 3 ): 409 - 422 .
Gaschler MM , Andia AA , Liu H , et al . FINO 2 initiates ferroptosis through GPX4 inactivation and iron oxidation [J ] . Nat Chem Biol , 2018 , 14 ( 5 ): 507 - 515 .
Zhang L , Hobeika CS , Khabibullin D , et al . Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11 [J ] . Proc Natl Acad Sci USA , 2022 , 119 ( 28 ): e2122840119 .
吴明哲 , 潘浩杰 , 周安安 , 等 . 铁死亡调控的关键因子在肾癌中的研究进展 [J ] . 中国医药 , 2023 , 18 ( 3 ): 472 - 476 .
Wu MZ , Pan HJ , Zhou AA , et al . Research progress of key factors of ferroptosis regulation in kidney cancer [J ] . China Medicine , 2023 , 18 ( 3 ): 472 - 476 .
Li X , Xiong W , Wang Y , et al . p53 activates the lipoxygenase activity of ALOX15B via inhibiting SLC7A11 to induce ferroptosis in bladder cancer cells [J ] . Lab Invest , 2023 , 103 ( 5 ): 100058 .
Drayton RM , Dudziec E , Peter S , et al . Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11 [J ] . Clin Cancer Res , 2014 , 20 ( 7 ): 1990 - 2000 .
Shen L , Zhang J , Zheng Z , et al . PHGDH inhibits ferroptosis and promotes malignant progression by upregulating SLC7A11 in bladder cancer [J ] . Int J Biol Sci , 2022 , 18 ( 14 ): 5459 - 5474 .
Sun Y , Berleth N , Wu W , et al . Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells [J ] . Cell Death Dis , 2021 , 12 ( 11 ): 1028 .
Yan Y , Cai J , Huang Z , et al . A novel ferroptosis-related prognostic signature reveals macrophage infiltration and EMT status in bladder cancer [J ] . Front Cell Dev Biol , 2021 , 9 : 712230 .
0
Views
5
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621
